TABLE OF CONTENTS

1. INTRODUCTION 19
1.1. OBJECTIVES OF THE STUDY 19
1.2. MARKET DEFINITION 19
1.3. OVERVIEW OF EUROPE CHOLESTEROL TESTING MARKET 19
1.4. CURRENCY AND PRICING 20
1.5. LIMITATION 20
1.6. MARKETS COVERED 21
2. MARKET SEGMENTATION 23
2.1. MARKETS COVERED 23
2.2. GEOGRAPHIC SCOPE 24
2.3. YEARS CONSIDERED FOR THE STUDY 25
2.4. CURRENCY AND PRICING 25
2.5. RESEARCH METHODOLOGY 26
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.7. SECONDARY SOURCES 30
2.8. ASSUMPTIONS 30
3. EXECUTIVE SUMMARY 31
4. MARKET OVERVIEW 34
4.1. DRIVERS 36
4.2. RESTRAINTS 37
4.3. OPPORTUNITIES 38
4.4. CHALLENGES 39
5. PREMIUM INSIGHTS 40
6. EUROPE CHOLESTEROL TESTING MARKET, BY PRODUCT TYPE 41
6.1. OVERVIEW 42
6.2. TESTING STRIPS 44
6.3. TEST KITS 45
7. EUROPE CHOLESTEROL TESTING MARKET, BY TEST 46
7.1. OVERVIEW 47
7.2. LIPID PANEL TEST/COMPLETE LIPID PROFILE 49
7.2.1. TOTAL CHOLESTEROL TEST 50
7.2.2. HDL CHOLESTEROL TEST 50
7.2.3. LDL CHOLESTEROL TEST 51
7.2.4. TRIGLYCERIDES/VLDL CHOLESTEROL TEST 51
7.3. APOLIPOPROTEIN B TEST 52
7.4. APOLIPOPROTEIN A-1 TEST 53
7.5. APOE GENOTYPING TEST 54
7.6. APOLIPOPROTEIN CII 55
7.7. OTHERS 56
8. EUROPE CHOLESTEROL TESTING MARKET, BY TEST TYPE 57
8.1. OVERVIEW 58
8.2. NON-INVASIVE 60
8.3. INVASIVE 61
9. EUROPE CHOLESTEROL TESTING MARKET, BY PRESCRIPTION MODE 62
9.1. OVERVIEW 63
9.2. OVER THE COUNTER 65
9.3. PRESCRIPTION BASED 66
10. EUROPE CHOLESTEROL TESTING MARKET, BY END-USERS 67
10.1. OVERVIEW 68
10.2. CLINICS 70
10.3. HOSPITALS 71
10.4. AMBULATORY CENTERS 72
10.5. HOMECARE 73
10.6. DIAGNOSTIC CENTERS 74
10.7. EUROPE 75
10.7.1. GERMANY 85
10.7.2. FRANCE 88
10.7.3. U.K. 92
10.7.4. ITALY 95
10.7.5. SPAIN 98
10.7.6. SWITZERLAND 101
10.7.7. NETHERLANDS 104
10.7.8. BELGIUM 107
10.7.9. RUSSIA 110
10.7.10. TURKEY 113
10.7.11. REST OF EUROPE 116
11. EUROPE CHOLESTEROL TESTING MARKET, COMPANY LANDSCAPE 117
11.1. COMPANY SHARE ANALYSIS; EUROPE 117
12. COMPANY PROFILES 119
12.1. BIO-RAD LABORATORIES, INC. 119
12.1.1. COMPANY OVERVIEW 119
12.1.2. BIO-RAD LABORATORIES, INC.; REVENUE ANALYSIS 119
12.1.3. PRODUCT PORTFOLIO 120
12.1.4. RECENT DEVELOPMENTS 120
12.2. ABBOTT 121
12.2.1. COMPANY OVERVIEW 121
12.2.2. ABBOTT; REVENUE ANALYSIS 121
12.2.3. PRODUCT PORTFOLIO 122
12.2.4. RECENT DEVELOPMENTS 122
12.3. SIEMENS AG 123
12.3.1. COMPANY OVERVIEW 123
12.3.2. SIEMENS AG; REVENUE ANALYSIS 123
12.3.3. PRODUCT PORTFOLIO 124
12.3.4. RECENT DEVELOPMENTS 124
12.4. ALERE INC. 125
12.4.1. COMPANY OVERVIEW 125
12.4.2. ALERE INC.; REVENUE ANALYSIS 125
12.4.3. PRODUCT PORTFOLIO 126
12.4.4. RECENT DEVELOPMENTS 126
12.5. SIGMA ALDRICH (A SUBSIDIARY OF MERCK KGAA) 127
12.5.1. COMPANY OVERVIEW 127
12.5.2. MERCK KGAA; REVENUE ANALYSIS 127
12.5.3. PRODUCT PORTFOLIO 128
12.5.4. RECENT DEVELOPMENTS 128
12.6. F. HOFFMANN-LA ROCHE LTD 129
12.6.1. COMPANY OVERVIEW 129
12.6.2. F. HOFFMANN-LA ROCHE LTD;REVENUE ANALYSIS 129
12.6.3. PRODUCT PORTFOLIO 130
12.6.4. RECENT DEVELOPMENTS 130
12.7. DANAHER 131
12.7.1. COMPANY OVERVIEW 131
12.7.2. DANAHER; REVENUE ANALYSIS 131
12.7.3. PRODUCT PORTFOLIO 132
12.7.4. RECENT DEVELOPMENTS 132
12.8. QUEST DIAGNOSTICS INCORPORATED 133
12.8.1. COMPANY OVERVIEW 133
12.8.2. QUEST DIAGNOSTICS INCORPORATED; REVENUE ANALYSIS 133
12.8.3. PRODUCT PORTFOLIO 134
12.8.4. RECENT DEVELOPMENTS 134
12.9. ACCUTECH, LLC 135
12.9.1. COMPANY OVERVIEW 135
12.9.2. ACCUTECH, LLC; COMPANY SNAPSHOT 135
12.9.3. PRODUCT PORTFOLIO 135
12.9.4. RECENT DEVELOPMENTS 135
12.10. PRIMA LAB SA 136
12.10.1. COMPANY OVERVIEW 136
12.10.2. PRIMA LAB SA; COMPANY SNAPSHOT 136
12.10.3. PRODUCT PORTFOLIO 136
12.10.4. RECENT DEVELOPMENTS 136
12.11. HOME ACCESS HEALTH CORPORATION 137
12.11.1. COMPANY OVERVIEW 137
12.11.2. HOME ACCESS HEALTH CORPORATION; COMPANY SNAPSHOT 137
12.11.3. PRODUCT PORTFOLIO 137
12.11.4. RECENT DEVELOPMENTS 137
12.12. EUROFINS SCIENTIFIC 138
12.12.1. COMPANY OVERVIEW 138
12.12.2. EUROFINS SCIENTIFIC; REVENUE ANALYSIS 138
12.12.3. PRODUCT PORTFOLIO 139
12.12.4. RECENT DEVELOPMENTS 139
12.13. RANDOX LABORATORIES LTD. 140
12.13.1. COMPANY OVERVIEW 140
12.13.2. RANDOX LABORATORIES LTD.; COMPANY SNAPSHOT 140
12.13.3. PRODUCT PORTFOLIO 140
12.13.4. RECENT DEVELOPMENTS 140
12.14. PTS DIAGNOSTICS 141
12.14.1. COMPANY OVERVIEW 141
12.14.2. PTS DIAGNOSTIC; COMPANY SNAPSHOT 141
12.14.3. PRODUCT PORTFOLIO 142
12.14.4. RECENT DEVELOPMENTS 142
13. RELATED REPORTS 143

?